Therapeutics - Transplant 3

Card Set Information

Author:
kyleannkelsey
ID:
300297
Filename:
Therapeutics - Transplant 3
Updated:
2015-04-08 18:14:37
Tags:
Therapeutics Transplant
Folders:

Description:
Therapeutics - Transplant
Show Answers:

Home > Flashcards > Print Preview

The flashcards below were created by user kyleannkelsey on FreezingBlue Flashcards. What would you like to do?


  1. Is Tacrolimus (FK506) or Cyclosporine (CsA) more likely to cause HYPERlipidemia?
    • CsA
    • Treat aggressively
  2. Is Tacrolimus (FK506) or Cyclosporine (CsA) more likely to cause Myocardial Hypertrophy?
    • Same risk
    • May be due to HTN
  3. Is Tacrolimus (FK506) or Cyclosporine (CsA) more likely to cause Hirsutism?
    CsA
  4. Is Tacrolimus (FK506) or Cyclosporine (CsA) more likely to cause Alopecia?
    FK
  5. Is Tacrolimus (FK506) or Cyclosporine (CsA) more likely to cause electrolyte imbalances?
    Same risk
  6. What types of electrolyte imbalances are common with Calcineurin inhibitors?
    Increased K and decreased Mg
  7. What drugs cause increased Calcineurin inhibitor levels?
    • Azoles
    • Dilt/Verap
    • Macrolides (Azith, Clarith, Eryth, Telith)
    • PIs
    • Grapefruit juice
  8. What drugs cause decreased Calcineurin Inhibitor levels?
    • Phenytoin, Phenobarbital, Carbamazepine
    • Rifampin
    • St. John’s Wart
  9. What is the MOA of Sirolimus (Rapamune)?
    • Macrolide immunosuppressant
    • Binds to FK, which binds to mTOR
    • Inhibits T cell proliferation by inhibiting cellular response to IL-2
    • Prevents B cell differentiation/antibody production
    • Also has antifungal and antitumor properties
  10. When is Sirolimus (Rapamune) used/not used?
    • Renal transplants (low-high risk)
    • Higher risk of hepatic artery thrombosis = so not best for liver transplant
  11. What are the dosing/admin considerations for Sirolimus (Rapamune)?
    • No body weight dosing
    • Load: 6 mg PO ASAP postop
    • Maintenance: 2 mg PO QD
    • 1 & 2 mg tablets
    • Avoid light
    • Refrigerate
  12. What monitoring should be done for Sirolimus (Rapamune)?
    • 1st year Trough: 16-24 ng/mL
    • > 1 year postop Trough: 12-20 ng/mL
    • Concurrently w/ CsA: 10-15 ng/mL
  13. What are the AE for Sirolimus (Rapamune)?
    • Leukopenia
    • Thrombocytopenia
    • Hyperlipidemia
    • CYP3A4 and pgp substrate and inhibitor
    • Vori and Keto CI (increases conc 10x)
  14. When is Everolimus (Zortress) used/not used?
    • Only for Kidney Transplant LOW-MOD
    • Not used in severe risk patients
  15. What are the dosing/admin concerns for Everolimus (Zortress)?
    • No loading dose
    • Take w/ or w/o food, but be consistent
  16. What is the MOA for corticosteroids?
    • Inhibition of Cytokines (IL-1,2,3,6 & TNFa)
    • Interfere w/ cell migration and recognition
    • Inhibition IL-1 secretion from macrophages
    • Decreased IL-2 secretion from T cells
    • Inhibit generation of CD8+ T cells
  17. What is a normal dose of Corticosteroids during induction?
    IV methylpred 3 mg/kg
  18. What is a normal dose of Corticosteroids during maintenance therapy?
    • IV Methylpred Postop day 1: 0.5-2 mg/kg
    • Transition to PO
    • Taper over next months to 5-20 mg QD
  19. What drugs are considered Calcineurin Inhibitor sparing?
    Corticosteroids
  20. What are the AE of Corticosteroids?
    • CNS
    • HTN
    • Infection
    • Increased appetite/weight
    • OP
    • Cataracts
    • Glucose intolerance
    • HLD
    • Cushing’s
  21. What is the MOA of Mycophenolate (MMF)?
    • Selective, reversible inhibitor or inosine monophosphate dehydrogenase (IMPDH) needed for purine synthesis
    • Specific for T cells and B cells (more so than Azathioprine)
  22. When is Mycophenolate (MMF) used/not used?
    • Common for both liver and kidney disease
    • In combo with a Calcineurin inhibitor
  23. What are the pharmacokinetics of Mycophenolate (MMF)?
    • Absorption of 75% or more
    • Increased AUC may occur after chronic use due to enterohepatic recirculation – dose adjust as needed
    • Hepatic metabolism
    • Renal tubular secretion
  24. What DDIs does Mycophenolate have?
    • Increases Acyclovir and probenecid – competes for renal tubular secretion
    • Bile acid resins (cholestyramine, etc.) and Al or Mg based antacids – decrease MMF by 40%
  25. What Antacids are AL or Mg containing?
    • Mg: Equate, Maalox lq, Milk of Magnesia, Rennie, Mylanta, Rolaids and Gelusil
    • Al: Equate, Malox lq and Tabs, Mylanta and Gelusil
  26. What are the dosing/admin concerns for Mycophenolate (MMF)?
    • 100 mg Cellcept: 720 mg Myfortic
    • Cellcept: 1-1.5g BID, 250 caps and 500 mg tabs
    • Myfortic: 720 BID PO, 180 mg and 360mg tabs – better if GI issues occur with Cellcept

What would you like to do?

Home > Flashcards > Print Preview